Abstract：
Purpose: The purpose of this case report is to describe spasticity and encephalopathy that developed in a multiple sclerosis patient following carbapenem administration. Summary: A 55-year-old female with multiple sclerosis developed spasticity and encephalopathy within 24 hours of meropenem and ertapenem administration. This was the second time that she had developed encephalopathy following carbapenem administration. The patient gradually recovered over four days following discontinuation of carbapenem therapy. Conclusion: Carbapenem neurotoxicity, a well-documented adverse effect, has been linked to several risk factors, including central nervous system lesions. Despite this, there is little evidence describing the risk of neurotoxicity in patients with multiple sclerosis. It is important to understand the potential adverse effects of carbapenems in specific patient populations to help guide appropriate treatment of infections.
摘要：
目的：本病例报告的目的是描述碳青霉烯给药后多发性硬化症患者的痉挛和脑病。摘要：一名55岁的多发性硬化症女性在美罗培南和厄他培南给药24小时内出现痉挛和脑病。这是她第二次在碳青霉烯给药后出现脑病。停止碳青霉烯治疗后，患者在四天内逐渐康复。结论:碳青霉烯神经毒性,一个有据可查的不利影响，与几个风险因素有关，包括中枢神经系统病变.尽管如此,几乎没有证据描述多发性硬化症患者的神经毒性风险。重要的是要了解碳青霉烯类抗生素在特定患者人群中的潜在不良反应，以帮助指导适当的感染治疗。
